Browse PLCE1

Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol. Cell membrane. Golgi apparatus membrane. Note=Recruited to plasma membrane by activated HRAS and RAP2. Recruited to perinuclear membrane by activated RAP1A. Isoform 1 and isoform 2 associates with Golgi membranes.
Domain PF00168 C2 domain
PF09279 Phosphoinositide-specific phospholipase C
PF00388 Phosphatidylinositol-specific phospholipase C
PF00387 Phosphatidylinositol-specific phospholipase C
PF00788 Ras association (RalGDS/AF-6) domain
PF00617 RasGEF domain
Function

The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. PLCE1 is a bifunctional enzyme which also regulates small GTPases of the Ras superfamily through its Ras guanine-exchange factor (RasGEF) activity. As an effector of heterotrimeric and small G-protein, it may play a role in cell survival, cell growth, actin organization and T-cell activation.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001558 regulation of cell growth
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0003012 muscle system process
GO:0006066 alcohol metabolic process
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006644 phospholipid metabolic process
GO:0006651 diacylglycerol biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006939 smooth muscle contraction
GO:0006940 regulation of smooth muscle contraction
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007507 heart development
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0016042 lipid catabolic process
GO:0016049 cell growth
GO:0019722 calcium-mediated signaling
GO:0019751 polyol metabolic process
GO:0019932 second-messenger-mediated signaling
GO:0032147 activation of protein kinase activity
GO:0032835 glomerulus development
GO:0033674 positive regulation of kinase activity
GO:0038127 ERBB signaling pathway
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043647 inositol phosphate metabolic process
GO:0044057 regulation of system process
GO:0045017 glycerolipid biosynthetic process
GO:0045860 positive regulation of protein kinase activity
GO:0046339 diacylglycerol metabolic process
GO:0046460 neutral lipid biosynthetic process
GO:0046463 acylglycerol biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046578 regulation of Ras protein signal transduction
GO:0048016 inositol phosphate-mediated signaling
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0090257 regulation of muscle system process
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0005057 receptor signaling protein activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0017016 Ras GTPase binding
GO:0031267 small GTPase binding
GO:0042578 phosphoric ester hydrolase activity
GO:0051020 GTPase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04919 Thyroid hormone signaling pathway
hsa00562 Inositol phosphate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1483249: Inositol phosphate metabolism
R-HSA-1430728: Metabolism
R-HSA-1855204: Synthesis of IP3 and IP4 in the cytosol
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLCE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLCE1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLCE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6160.0316
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8950.0767
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4060.339
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1710.622
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.250.92
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0630.983
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2920.524
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3370.712
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2810.77
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7940.248
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6740.056
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1110.561
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLCE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.85.59.30.206
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.86.880.252
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.127.3-4.21
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113023.1-23.10.223
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLCE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLCE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLCE1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLCE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLCE1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLCE1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLCE1
Namephospholipase C, epsilon 1
Aliases KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ......
Chromosomal Location10q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLCE1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.